Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Joaquim Bellmunt(Dana-Farber Cancer Institute), Vesa Kataja(Kuopio University Hospital), Thomas Wiegel(University Hospital Ulm), Anna Orsola(Hebron University), Marta Guix(Hospital Del Mar), Maria De Santis(Medical University of Vienna)

Annals of Oncology

September 1, 2011

10.1093/annonc/mdr376

Cited by 249

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|3.7k

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

|New England Journal of Medicine|2017|3.4k

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

|Nature|2014|2.4k

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|2.2k

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

|New England Journal of Medicine|2020|1.5k